Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX.
Fiche publication
Date publication
juillet 2020
Journal
Anticancer research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François, Dr VINCENT Julie, Dr BENGRINE-LEFEVRE Leila, Dr FUMET Jean-David, Dr HENNEQUIN Audrey
Tous les auteurs :
Fumet JD, Vincent J, Bengrine L, Hennequin A, Granconato L, Palmier R, Ghiringhelli F
Lien Pubmed
Résumé
The aim of this monocentric study was to evaluate the efficacy and tolerability of a polychemotherapy regimen based on gemcitabine, docetaxel, capecitabine, cisplatin (PDGX) as second-line for advanced pancreatic cancer after FOLFIRINOX.
Mots clés
Pancreatic cancer, capecitabine, chemotherapy, cisplatin, docetaxel, gemcitabine
Référence
Anticancer Res.. 2020 Jul;40(7):4011-4015